The authors examined the relevance of S-phase fraction ( SPF ) and multidrug resistance ( MDR ) phenotype as predictive tests of breast cancer response in a series of patients treated by conventional doses of neoadjuvant chemotherapy with ( FAC ) or without ( FTC ) doxorubicin .
